|
Apr 16
|
Boehringer and Cue Biopharma to develop autoimmune therapies
|
|
Apr 15
|
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering
|
|
Apr 14
|
Cue Biopharma Announces Proposed Public Offering
|
|
Apr 14
|
Cue Biopharma to Host Business Update Call and Webcast
|
|
Apr 14
|
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
|
|
Oct 8
|
Cue Biopharma (NASDAQ:CUE) adds US$31m to market cap in the past 7 days, though investors from three years ago are still down 89%
|
|
Jul 26
|
Cue Biopharma downsizes to focus on autoimmune pipeline
|
|
Jul 25
|
Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements
|
|
Jun 21
|
Xoma (XOMA) Soars 15.6%: Is Further Upside Left in the Stock?
|
|
Jun 4
|
Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
|
|
Jun 3
|
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024
|
|
May 11
|
Cue Biopharma First Quarter 2024 Earnings: Beats Expectations
|
|
May 9
|
Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
|
|
May 8
|
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
|
|
May 7
|
Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference
|
|
Apr 25
|
Here's Why Cue Biopharma (CUE) is Poised for a Turnaround After Losing -22.83% in 4 Weeks
|
|
Apr 24
|
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
Apr 15
|
Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now
|
|
Apr 9
|
Q4 2023 Cue Biopharma Inc Earnings Call
|
|
Apr 9
|
Cue Biopharma Inc (CUE) Q4 2023 Earnings Call Transcript Highlights: Strategic Alliances and ...
|